Sanofi, GSK prolong Phase 3 trial of COVID-19 vaccine booster candidate
PARIS, Dec. 15 (Xinhua) -- The single booster dose of the COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline (GSK) is in its late-stage (Phase 3
Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PARIS, Dec. 15 (Xinhua) -- The single booster dose of the COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline (GSK) is in its late-stage (Phase 3
"These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received"
Early trials show jab effective in people of all ages who have already received doses of any vaccine
Sanofi and GlaxoSmithKline on Wednesday reported that their potential COVID-19 booster shot delivered good immune response in its preliminary clinical trials.
Sanofi is to acquire Origimm Biotechnology in a move that gives the pharma giants a candidate to develop a first-in-class acne vaccine, which targets the skin microbiome and bacterial antigens that cause the skin condition.